KKR, through a consortium of its funds, announced a follow‑on investment in Sylvan on January 20, 2026, reinforcing its majority ownership stake in the world‑leading fungal biotechnology company.
The transaction was led by KKR’s international and domestic funds, including its first renminbi‑denominated fund, and attracted new investors such as TPG NewQuest, Ping’An Capital, China Post Insurance, Schroders Capital and Tsao Pao Chee. Novo Holdings also increased its stake, underscoring confidence from a planetary‑health‑focused investor.
Sylvan, founded in 1932, has built a global reputation for developing sustainable solutions in food, health, agriculture and materials through fungal systems. The company’s technology enables high‑yield, low‑resource production of proteins, enzymes and other bioproducts that replace conventional animal‑based or chemical processes.
The new capital will be deployed to expand Sylvan’s production capacity, strengthen research and development, and accelerate entry into high‑growth product categories across Asia and worldwide. KKR’s continued majority ownership signals strong confidence in Sylvan’s growth strategy and management team, while the participation of local and international investors provides both financial resources and market expertise.
"This investment allows us to accelerate our ambition to become a global leader in fungal biotechnology solutions across strategies and regions," said Jacki Qi, Sylvan CEO. "We are grateful for KKR’s sustained partnership and the support of our new investors, which will help us scale our platform and broaden our global reach," added Chris Sun, KKR partner and head of China private equity.
The fungal biotechnology market is projected to grow at a CAGR of over 5.6% from 2025 to 2034, reaching an estimated USD 117.1 million by 2034. Sylvan’s focus on sustainable protein and material alternatives aligns with rising ESG demand and the global shift toward plant‑based and low‑resource production methods.
With this follow‑on round, Sylvan is positioned to capture a larger share of the rapidly expanding fungal biotechnology market, while KKR’s confidence and the involvement of a diverse investor group reinforce the company’s ability to scale and innovate in a high‑growth, sustainability‑driven sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.